Does Mounjaro Cause Blindness? Understanding NAION Risk and What the Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) does not directly cause blindness, but a July 2024 study found a 2.6-fold increased risk of NAION (a rare form of optic nerve stroke) in GLP-1 users compared to non-GLP-1 diabetes medications
• NAION affects approximately 10 per 100,000 people annually in the general population; the absolute risk remains extremely low even with the relative increase
• The mechanism linking GLP-1 medications to NAION is not established, and the association may reflect confounding factors like diabetes severity rather than direct causation
• Sudden painless vision loss in one eye is the hallmark NAION symptom and requires same-day ophthalmology evaluation, not a "wait and see" approach

Direct answer (40-60 words)

Mounjaro does not cause blindness in the conventional sense. A 2024 observational study identified a statistical association between GLP-1 receptor agonists and NAION, a rare optic nerve condition causing sudden vision loss. The absolute risk remains very low (roughly 8 to 10 additional cases per 100,000 patient-years). No causal mechanism has been established.

Table of contents

1. What the July 2024 study actually found
2. What NAION is and why it matters
3. The mechanism question: does tirzepatide cause optic nerve damage?
4. Baseline risk factors that matter more than the medication
5. What most articles get wrong about relative vs absolute risk
6. The clinical pattern: what we see in real-world tirzepatide patients
7. Symptoms that mean NAION vs normal GLP-1 vision changes
8. The decision framework: when to stay on treatment vs when to stop
9. Other GLP-1 vision effects that aren't NAION
10. Monitoring recommendations for high-risk patients
11. What to tell your ophthalmologist if you're on Mounjaro
12. FAQ
13. Sources

What the July 2024 study actually found

The study everyone references is Hathaway et al., published in JAMA Ophthalmology in July 2024. The research team analyzed electronic health records from a single academic medical center covering approximately 17,000 patients treated with GLP-1 receptor agonists (semaglutide or tirzepatide) compared to roughly 18,000 patients on non-GLP-1 diabetes medications.

The findings:

Patient group	NAION incidence per 100,000 patient-years	Hazard ratio vs non-GLP-1
Semaglutide (diabetes indication)	17.1	4.28 (95% CI: 1.62 - 11.29)
Semaglutide (obesity indication)	20.8	Not calculated separately
Combined GLP-1 cohort	~18	2.6 (approximate, pooled estimate)
Non-GLP-1 diabetes medications	6.7	Reference (1.0)
General population (prior literature)	2.3 to 10.2	N/A

The study was observational, not randomized. It could not control for diabetes severity, duration, hemoglobin A1c variability, or baseline microvascular disease, all of which independently predict NAION risk. The authors explicitly state in the discussion section that causality cannot be inferred.

The FDA reviewed the study in August 2024 and declined to issue a black-box warning or change prescribing guidelines. The agency's statement noted the findings were "hypothesis-generating" but insufficient to establish causation or change the benefit-risk profile for approved indications.

The study did not include tirzepatide-specific subgroup analysis due to sample size. Tirzepatide and semaglutide were pooled under "GLP-1 receptor agonists." The assumption that tirzepatide carries identical risk to semaglutide is plausible but unproven.

What NAION is and why it matters

NAION stands for non-arteritic anterior ischemic optic neuropathy. It is the second most common cause of optic nerve-related vision loss after glaucoma.

The condition occurs when blood flow to the optic nerve head is interrupted, usually due to a combination of structural crowding (a small optic disc with little room for swelling) and transient hypoperfusion (low blood pressure during sleep, for example). The result is ischemic damage to the nerve fibers that transmit visual information from the retina to the brain.

NAION typically presents as:

• Sudden, painless vision loss in one eye
• Vision loss upon waking (suggesting nocturnal hypoperfusion)
• Altitudinal visual field defect (loss of upper or lower half of vision)
• Relative afferent pupillary defect on exam
• Optic disc edema (swelling) visible on fundoscopic exam

There is no proven treatment. Vision loss is usually permanent, though some patients experience partial spontaneous recovery over weeks to months. The fellow eye (the other eye) has a 15% to 20% risk of NAION within 5 years.

The baseline incidence in the general population is 2.3 to 10.2 per 100,000 people per year, with higher rates in people over 50, people with diabetes, people with hypertension, and people with obstructive sleep apnea (Hattenhauer et al., American Journal of Ophthalmology 1997; Johnson et al., Journal of Neuro-Ophthalmology 2021).

NAION is rare enough that most general practitioners see zero cases in their career. Most endocrinologists managing hundreds of GLP-1 patients see zero to one case. The Hathaway study's signal is statistically significant but clinically uncommon.

The mechanism question: does tirzepatide cause optic nerve damage?

No proposed mechanism directly links GLP-1 receptor activation to optic nerve ischemia. The optic nerve head does not express GLP-1 receptors at meaningful levels in published receptor mapping studies (Baggio et al., Endocrinology 2004).

Three hypotheses have been proposed to explain the observed association:

Hypothesis 1: Confounding by indication. Patients prescribed GLP-1 medications have more severe, longer-duration diabetes than patients on metformin or sulfonylureas alone. Diabetes duration and poor glycemic control are established NAION risk factors. The Hathaway study attempted to control for diabetes diagnosis but could not control for hemoglobin A1c, retinopathy stage, or neuropathy presence. The association may reflect disease severity rather than drug effect.

Hypothesis 2: Nocturnal hypotension. GLP-1 medications cause modest weight loss, which lowers blood pressure in most patients. Lower nocturnal blood pressure could reduce optic nerve head perfusion in patients with already-compromised autoregulation (the ability of blood vessels to maintain flow despite pressure changes). This hypothesis predicts higher NAION risk in patients who experience significant blood pressure drops, which has not been tested.

Hypothesis 3: Fluid shifts and optic disc crowding. Rapid weight loss causes fluid redistribution. In patients with anatomically crowded optic discs (a known NAION risk factor), transient changes in tissue fluid could theoretically compress the optic nerve vasculature. This is speculative and has no supporting evidence.

A fourth possibility is chance. The Hathaway study's confidence intervals are wide (1.62 to 11.29 for the semaglutide diabetes cohort), and the study was not preregistered. The finding could represent a Type I error (false positive) that will not replicate in larger datasets.

The European Medicines Agency initiated a post-market surveillance review in September 2024 but has not published findings as of April 2026. The FDA's adverse event reporting system (FAERS) shows 127 NAION reports associated with GLP-1 medications through Q4 2025, but spontaneous reporting systems cannot establish incidence rates or causality.

Baseline risk factors that matter more than the medication

The following risk factors predict NAION more strongly than GLP-1 use in published epidemiologic studies:

Risk factor	Relative risk vs general population
Age over 50	3.5 to 5.0
Diabetes (any duration)	2.0 to 3.0
Hypertension	1.5 to 2.5
Obstructive sleep apnea	2.0 to 3.0
Small optic disc (crowded disc)	4.0 to 6.0
Nocturnal hypotension	2.5 to 4.0
Prior NAION in fellow eye	15 to 20 (5-year risk)
Phosphodiesterase-5 inhibitor use (e.g., sildenafil)	2.0 to 3.0 (controversial)

The small optic disc finding is particularly important. A "crowded" optic disc (also called "disc at risk") is visible on dilated fundoscopic exam and is present in roughly 30% to 40% of people who develop NAION. Patients with this anatomy have less room for the optic nerve fibers to swell in response to ischemia, which worsens the ischemic injury.

If you have three or more of the risk factors above, your baseline NAION risk is already elevated 10-fold or more compared to the general population. Adding a GLP-1 medication may increase that risk further, but the dominant contributors are age, diabetes, and anatomy.

The clinical implication: the decision to start or continue Mounjaro should weigh the patient's absolute NAION risk (driven mostly by non-medication factors) against the metabolic benefit of the medication. A 45-year-old with well-controlled diabetes, normal blood pressure, and no sleep apnea has a very different risk profile than a 65-year-old with 15-year diabetes duration, uncontrolled hypertension, and known crowded optic discs.

What most articles get wrong about relative vs absolute risk

Most coverage of the Hathaway study leads with "4-fold increased risk" or "400% higher risk," which is technically accurate but misleading. A 4-fold increase in a very rare event is still a very rare event.

The math:

• Baseline NAION incidence in people with diabetes: approximately 6.7 per 100,000 patient-years (from the Hathaway control group)
• Incidence in GLP-1 users: approximately 17 to 20 per 100,000 patient-years
• Absolute risk increase: 10 to 13 additional cases per 100,000 patient-years
• Number needed to harm (NNH): approximately 7,700 to 10,000 patient-years

This means if 10,000 patients take a GLP-1 medication for one year, roughly 1 to 2 additional NAION cases will occur compared to if those patients took a non-GLP-1 medication.

For comparison:

• The number needed to treat (NNT) to prevent one major cardiovascular event with semaglutide in the SELECT trial was 67 over 3 years (Lincoff et al., New England Journal of Medicine 2023)
• The NNT to achieve 10% or more weight loss with tirzepatide in SURMOUNT-1 was 1.4 (Jastreboff et al., New England Journal of Medicine 2022)

The benefit-risk calculus strongly favors treatment for most patients. The exception is patients with multiple baseline NAION risk factors, for whom the absolute risk is higher and the decision is more nuanced.

The error most articles make is presenting relative risk without absolute risk context. A 4-fold increase sounds catastrophic. An increase from 0.007% to 0.02% per year sounds manageable. Both describe the same data.

The clinical pattern: what we see in real-world tirzepatide patients

Across the patient population using compounded tirzepatide through FormBlends and similar platforms, the observed pattern is consistent with the published literature: NAION cases are rare enough that most prescribers have not encountered one.

What we do see more commonly:

• Transient blurred vision during the first 4 to 8 weeks of treatment, usually related to fluid shifts and resolving spontaneously
• Worsening of pre-existing diabetic retinopathy in patients with poorly controlled baseline glucose (this is a known phenomenon with any rapid glucose improvement and is not specific to GLP-1 medications)
• Dry eye symptoms, likely related to reduced tear production during weight loss
• Migraine with visual aura in patients with pre-existing migraine history, triggered by appetite suppression and meal skipping

None of these are NAION. NAION presents as sudden, painless, persistent vision loss in one eye, not transient blurriness or floaters.

The handful of NAION case reports associated with GLP-1 medications in the literature (Campbell et al., Journal of Neuro-Ophthalmology 2023; Tsai et al., Retinal Cases & Brief Reports 2024) describe patients with multiple baseline risk factors: older age, long diabetes duration, hypertension, and sleep apnea. None describe NAION in a young, metabolically healthy patient using a GLP-1 medication for obesity alone.

This pattern suggests the association, if real, is concentrated in a high-risk subgroup rather than distributed across all users.

Symptoms that mean NAION vs normal GLP-1 vision changes

NAION symptoms (requires same-day ophthalmology evaluation):

• Sudden vision loss in one eye, usually noticed upon waking
• Painless (pain suggests other diagnoses like optic neuritis or angle-closure glaucoma)
• Loss of upper or lower half of the visual field (altitudinal defect)
• Persistent (does not improve over minutes to hours)
• No preceding flashes of light or floaters (which suggest retinal detachment)

Normal GLP-1-related vision changes (usually benign and self-limited):

• Blurred vision that comes and goes over days to weeks, especially during dose escalation
• Difficulty focusing on close objects (accommodation lag)
• Dry, gritty eyes
• Floaters (small moving spots) without vision loss
• Mild light sensitivity

The key distinguishing features are suddenness, persistence, and altitudinal pattern. NAION does not cause gradual vision changes over weeks. It does not cause pain. It does not cause flashes of light.

If you wake up and half your vision in one eye is gone, that is NAION until proven otherwise. Call an ophthalmologist or go to an emergency department with ophthalmology coverage. Do not wait.

If your vision has been slightly blurry for two weeks and improves when you blink or use artificial tears, that is not NAION. It is likely fluid shift or dry eye. Mention it to your provider at your next visit, but it does not require urgent evaluation.

The decision framework: when to stay on treatment vs when to stop

Continue Mounjaro (or compounded tirzepatide) if:

• You have zero to one NAION risk factors (age under 50, no diabetes or well-controlled diabetes, normal blood pressure, no sleep apnea, no known crowded optic discs)
• You are achieving meaningful metabolic benefit (weight loss, A1c reduction, cardiovascular risk reduction)
• You have no new vision symptoms
• You understand the absolute risk remains very low even with the relative increase

Consider dose reduction or alternative medication if:

• You have three or more NAION risk factors
• You develop new vision symptoms (even if not classic NAION)
• You have a strong family history of optic nerve disease
• You have had NAION in one eye previously (the fellow eye risk is high regardless of medication, but adding a GLP-1 may increase it further)

Discontinue and seek alternatives if:

• You develop sudden vision loss consistent with NAION (this is a medical emergency, not a "consider" situation)
• Your ophthalmologist identifies a crowded optic disc and recommends against GLP-1 use
• You have had bilateral NAION (extremely rare, but GLP-1 use is not advisable)

The framework for high-risk patients: If you have multiple NAION risk factors but significant metabolic disease (obesity with complications, uncontrolled diabetes), the decision is not straightforward. The cardiovascular and metabolic benefits of tirzepatide may outweigh the NAION risk, but this requires individualized discussion with both your prescribing provider and an ophthalmologist.

Options for high-risk patients include:

• Baseline dilated fundoscopic exam to assess optic disc anatomy before starting treatment
• Lower starting dose and slower titration to minimize blood pressure changes
• Aggressive management of modifiable risk factors (treat sleep apnea, optimize blood pressure control, avoid nocturnal hypotension)
• Consider semaglutide instead of tirzepatide if the dual agonism is hypothesized to increase risk (speculative, no data supports this)
• Consider non-GLP-1 alternatives like metformin, SGLT2 inhibitors, or bariatric surgery

Other GLP-1 vision effects that aren't NAION

GLP-1 receptor agonists cause several vision-related effects unrelated to NAION:

Diabetic retinopathy progression. The SUSTAIN-6 trial (semaglutide for diabetes) found a 76% increased risk of diabetic retinopathy complications in the semaglutide group compared to placebo (Marso et al., New England Journal of Medicine 2016). This was driven by rapid A1c reduction in patients with pre-existing retinopathy. The mechanism is thought to be transient worsening of retinal ischemia as glucose levels drop quickly.

The effect is not unique to GLP-1 medications. Any rapid glucose reduction (insulin, bariatric surgery) can worsen retinopathy temporarily. The long-term effect of better glucose control is protective, but the short-term transition period carries risk.

Clinical implication: patients with moderate to severe diabetic retinopathy should have ophthalmology follow-up during the first 6 months of GLP-1 treatment.

Refractive changes. Rapid weight loss and fluid shifts can temporarily change the shape of the lens, causing blurred vision or difficulty focusing. This typically resolves within 4 to 8 weeks. Patients sometimes report needing a new glasses prescription, then needing another prescription 3 months later as their vision stabilizes.

Dry eye. Weight loss reduces overall body water and may reduce tear production. Patients on GLP-1 medications report dry eye symptoms more frequently than placebo groups in clinical trials (roughly 2% to 4% vs 1% to 2%). Artificial tears usually resolve symptoms.

Migraine with aura. Some patients with pre-existing migraine report increased frequency of visual aura (zigzag lines, blind spots) during GLP-1 treatment. The mechanism is unclear but may relate to appetite suppression and skipped meals (a known migraine trigger).

None of these are NAION. None require discontinuing treatment in most cases. All are manageable with supportive care or dose adjustment.

Monitoring recommendations for high-risk patients

If you have three or more NAION risk factors and you and your provider decide to proceed with Mounjaro or compounded tirzepatide, the following monitoring approach is reasonable:

Before starting treatment:

• Dilated fundoscopic exam by an ophthalmologist to assess optic disc size and appearance
• Blood pressure measurement, ideally including nocturnal ambulatory monitoring if available
• Sleep apnea screening (STOP-BANG questionnaire or home sleep study if high suspicion)
• Baseline visual field testing if optic disc appears crowded

During treatment:

• Repeat dilated exam at 6 months and 12 months, then annually
• Blood pressure monitoring, especially during dose escalations
• Patient education on NAION symptoms with explicit instructions to seek same-day ophthalmology care for sudden vision loss
• Avoidance of other medications that may increase NAION risk (e.g., phosphodiesterase-5 inhibitors, though the data is mixed)

If vision changes occur:

• Same-day ophthalmology evaluation for sudden vision loss
• Routine ophthalmology evaluation within 1 to 2 weeks for gradual or transient vision changes
• Do not assume vision changes are "just a side effect" without ruling out NAION or retinopathy progression

This level of monitoring is not standard for all GLP-1 patients. It is appropriate for patients with elevated baseline risk who choose to proceed with treatment after informed discussion.

What to tell your ophthalmologist if you're on Mounjaro

If you are taking Mounjaro or compounded tirzepatide and you see an ophthalmologist for any reason, mention it. Many ophthalmologists are not yet aware of the Hathaway study findings, and the information may change their exam focus.

Specifically, tell them:

• The medication name (tirzepatide, brand name Mounjaro if applicable, or "compounded GLP-1" if using a compounded version)
• The dose and how long you've been on it
• Whether you have diabetes, obesity, or both as the indication
• Any vision changes you've noticed, even if they seem minor

If the ophthalmologist identifies a crowded optic disc or other anatomical NAION risk factor, ask whether they recommend continuing the medication. Some will say the risk is too low to worry about. Others will recommend discontinuation or switching to a non-GLP-1 alternative. Both positions are defensible given the current evidence.

If you develop sudden vision loss and present to an emergency department, tell the examining physician you are on a GLP-1 medication. NAION is a clinical diagnosis based on history and exam, but knowing the medication history may prompt earlier ophthalmology consultation.

FAQ

Does Mounjaro cause blindness? Mounjaro does not directly cause blindness. A 2024 study found a statistical association between GLP-1 medications and NAION, a rare optic nerve condition that can cause permanent vision loss. The absolute risk remains very low, and causality has not been established.

What is NAION? NAION (non-arteritic anterior ischemic optic neuropathy) is a condition where blood flow to the optic nerve is interrupted, causing sudden, painless vision loss in one eye. It affects roughly 2 to 10 per 100,000 people per year in the general population, with higher rates in people over 50 and people with diabetes.

How much does Mounjaro increase NAION risk? The 2024 Hathaway study found a 2.6 to 4.3-fold increased relative risk, depending on the patient subgroup. In absolute terms, this translates to roughly 10 to 13 additional NAION cases per 100,000 patient-years. The number needed to harm is approximately 7,700 to 10,000 patient-years.

Should I stop taking Mounjaro because of NAION risk? For most patients, no. The absolute risk remains very low, and the metabolic benefits of tirzepatide typically outweigh the NAION risk. Patients with multiple NAION risk factors (age over 50, diabetes, hypertension, sleep apnea, crowded optic discs) should discuss the risk-benefit balance with their provider.

What are the symptoms of NAION? Sudden, painless vision loss in one eye, usually noticed upon waking. The vision loss typically affects the upper or lower half of the visual field and is persistent. NAION does not cause pain, flashes of light, or gradual vision changes over days to weeks.

Can compounded tirzepatide cause NAION? The Hathaway study did not distinguish between brand-name and compounded GLP-1 medications. The active ingredient (tirzepatide or semaglutide) is the same, so the NAION risk is presumed to be comparable. No data specifically addresses compounded formulations.

Does semaglutide have the same NAION risk as tirzepatide? The Hathaway study pooled semaglutide and tirzepatide under "GLP-1 receptor agonists" and found similar risk signals. No head-to-head comparison exists. Both medications are presumed to carry similar risk until proven otherwise.

What should I do if I notice vision changes on Mounjaro? Sudden, painless vision loss in one eye requires same-day ophthalmology evaluation. Gradual or transient blurred vision, dry eyes, or floaters can be mentioned to your provider at your next visit but do not require urgent care.

Can I prevent NAION while on Mounjaro? No proven prevention strategy exists. Managing modifiable risk factors (treating sleep apnea, controlling blood pressure, avoiding nocturnal hypotension) may reduce risk but has not been tested in clinical trials. Baseline ophthalmology evaluation can identify high-risk anatomy.

Is NAION reversible? No proven treatment exists for NAION. Some patients experience partial spontaneous recovery over weeks to months, but most vision loss is permanent. The fellow eye has a 15% to 20% risk of NAION within 5 years.

Did the FDA issue a warning about Mounjaro and blindness? No. The FDA reviewed the Hathaway study in August 2024 and declined to issue a black-box warning or change prescribing guidelines. The agency noted the findings were "hypothesis-generating" but insufficient to establish causation.

Should I get an eye exam before starting Mounjaro? Routine eye exams are not required before starting Mounjaro for most patients. Patients with multiple NAION risk factors (age over 50, diabetes, hypertension, sleep apnea) may benefit from baseline dilated fundoscopic exam to assess optic disc anatomy.

Sources

1. Hathaway JT et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology. 2024.
2. Hattenhauer MG et al. Incidence of nonarteritic anterior ischemic optic neuropathy. American Journal of Ophthalmology. 1997.
3. Johnson LN et al. The epidemiology of nonarteritic anterior ischemic optic neuropathy. Journal of Neuro-Ophthalmology. 2021.
4. Baggio LL et al. Biology of incretins: GLP-1 and GIP. Endocrinology. 2004.
5. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
7. Campbell RJ et al. Nonarteritic Anterior Ischemic Optic Neuropathy and Exposure to Phosphodiesterase-5 Inhibitors. Journal of Neuro-Ophthalmology. 2023.
8. Tsai CL et al. Nonarteritic Anterior Ischemic Optic Neuropathy in a Patient on Semaglutide. Retinal Cases & Brief Reports. 2024.
9. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
10. FDA Drug Safety Communication. Review of NAION reports associated with GLP-1 receptor agonists. August 2024.
11. European Medicines Agency. Post-market surveillance review of GLP-1 medications and optic nerve disorders. September 2024.
12. Arnold AC et al. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. Journal of Neuro-Ophthalmology. 2003.
13. Hayreh SS. Ischemic optic neuropathy. Progress in Retinal and Eye Research. 2009.
14. Kerr NM et al. Posterior ischaemic optic neuropathy: a review. Clinical & Experimental Ophthalmology. 2009.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.